332 related articles for article (PubMed ID: 26582823)
1. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims.
Solomon DH; Liu CC; Kuo IH; Zak A; Kim SC
Ann Rheum Dis; 2016 Sep; 75(9):1674-9. PubMed ID: 26582823
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.
Singh JA; Ramachandaran R; Yu S; Curtis JR
BMC Cardiovasc Disord; 2017 Mar; 17(1):76. PubMed ID: 28288564
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout.
Kang EH; Park EH; Shin A; Song JS; Kim SC
Eur Heart J; 2021 Nov; 42(44):4578-4588. PubMed ID: 34508567
[TBL] [Abstract][Full Text] [Related]
4. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the association between colchicine therapy and serious adverse events.
Todd BA; Billups SJ; Delate T; Canty KE; Kauffman AB; Rawlings JE; Wagner TM
Pharmacotherapy; 2012 Nov; 32(11):974-80. PubMed ID: 23019065
[TBL] [Abstract][Full Text] [Related]
6. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
7. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.
Crittenden DB; Lehmann RA; Schneck L; Keenan RT; Shah B; Greenberg JD; Cronstein BN; Sedlis SP; Pillinger MH
J Rheumatol; 2012 Jul; 39(7):1458-64. PubMed ID: 22660810
[TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.
Singh JA; Cleveland JD
Ann Rheum Dis; 2020 Apr; 79(4):529-535. PubMed ID: 32024648
[TBL] [Abstract][Full Text] [Related]
9. Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.
Kaul S; Gupta M; Bandyopadhyay D; Hajra A; Deedwania P; Roddy E; Mamas M; Klein A; Lavie CJ; Fonarow GC; Ghosh RK
Am J Cardiovasc Drugs; 2021 Sep; 21(5):499-512. PubMed ID: 33369719
[TBL] [Abstract][Full Text] [Related]
10. Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.
Roddy E; Bajpai R; Forrester H; Partington RJ; Mallen CD; Clarson LE; Padmanabhan N; Whittle R; Muller S
Ann Rheum Dis; 2023 Dec; 82(12):1618-1625. PubMed ID: 37788904
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout.
Kim SC; Neogi T; Kang EH; Liu J; Desai RJ; Zhang M; Solomon DH
J Am Coll Cardiol; 2018 Mar; 71(9):994-1004. PubMed ID: 29496000
[TBL] [Abstract][Full Text] [Related]
12. Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin.
Kwon OC; Hong S; Ghang B; Kim YG; Lee CK; Yoo B
Am J Med; 2017 May; 130(5):583-587. PubMed ID: 28065770
[TBL] [Abstract][Full Text] [Related]
13. Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: A 12-Year Cohort Study.
Kuo MC; Chang SJ; Hsieh MC
Medicine (Baltimore); 2015 Dec; 94(50):e1570. PubMed ID: 26683907
[TBL] [Abstract][Full Text] [Related]
14. Colchicine Use and Incident Coronary Artery Disease in Male Patients With Gout.
Shah B; Toprover M; Crittenden DB; Jeurling S; Pike VC; Krasnokutsky S; Xia Y; Fisher MC; Slobodnick A; Tenner CT; Katz SD; Pillinger MH
Can J Cardiol; 2020 Nov; 36(11):1722-1728. PubMed ID: 32454073
[TBL] [Abstract][Full Text] [Related]
15. Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout.
Wang L; Sawhney M; Zhao Y; Carpio GR; Fonseca V; Shi L
Clin Ther; 2015 Jun; 37(6):1206-15. PubMed ID: 25857595
[TBL] [Abstract][Full Text] [Related]
16. In older adults, new use of allopurinol or febuxostat was linked to hypersensitivity reactions versus colchicine.
Schattner A
Ann Intern Med; 2020 Jul; 173(2):JC10. PubMed ID: 32687746
[TBL] [Abstract][Full Text] [Related]
17. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.
Singh JA; Yu S
Ann Rheum Dis; 2017 Jan; 76(1):133-139. PubMed ID: 27296322
[TBL] [Abstract][Full Text] [Related]
18. Gout after living kidney donation: a matched cohort study.
Lam NN; McArthur E; Kim SJ; Prasad GV; Lentine KL; Reese PP; Kasiske BL; Lok CE; Feldman LS; Garg AX; ;
Am J Kidney Dis; 2015 Jun; 65(6):925-32. PubMed ID: 25818677
[TBL] [Abstract][Full Text] [Related]
19. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study.
Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
J Rheumatol; 2015 Sep; 42(9):1694-701. PubMed ID: 26077411
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
White WB; Chohan S; Dabholkar A; Hunt B; Jackson R
Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
